PMID- 33965978
OWN - NLM
STAT- MEDLINE
DCOM- 20210628
LR  - 20230917
IS  - 1473-6586 (Electronic)
IS  - 0963-0643 (Linking)
VI  - 31
IP  - 4
DP  - 2021 Jul 1
TI  - Adverse events of systemic immune-based combination therapies in the first-line 
      treatment of patients with metastatic renal cell carcinoma: systematic review and 
      network meta-analysis.
PG  - 332-339
LID - 10.1097/MOU.0000000000000889 [doi]
AB  - PURPOSE OF REVIEW: To compare the safety profiles of systemic immune checkpoint 
      inhibitor-based combination therapies that were evaluated in the first-line 
      setting of the management of patients with advanced or metastatic renal cell 
      carcinoma (mRCC). RECENT FINDINGS: Six phase III randomized control trials 
      comparing first-line immune-based combination therapies to sunitinib in 
      previously untreated patients with mRCC. Network meta-analyses were conducted to 
      compare treatment-related adverse events (TRAEs), treatment discontinuation, and 
      treatment-related mortality. SUMMARY: Lenvatinib plus pembrolizumab was 
      associated with the highest likelihood of grade >/=3 TRAEs, and treatment 
      discontinuation rates. Nivolumab plus ipilimumab was associated with the lowest 
      rates of grade >/=3 TRAEs. However, it was associated with a higher likelihood of 
      endocrine-related adverse events (AEs). A higher likelihood of high-grade 
      diarrhea was associated with pembrolizumab plus axitinib and avelumab plus 
      axitinib. All combinations showed low rates of hematological AEs.
CI  - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Quhal, Fahad
AU  - Quhal F
AD  - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 
      Vienna, Austria.
AD  - Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
FAU - Mori, Keiichiro
AU  - Mori K
AD  - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 
      Vienna, Austria.
AD  - Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
FAU - Remzi, Mesut
AU  - Remzi M
AD  - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 
      Vienna, Austria.
AD  - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.
FAU - Fajkovic, Harun
AU  - Fajkovic H
AD  - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 
      Vienna, Austria.
AD  - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.
FAU - Shariat, Shahrokh F
AU  - Shariat SF
AD  - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 
      Vienna, Austria.
AD  - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.
AD  - Department of Urology, Weill Cornell Medical College, New York, New York.
AD  - Department of Urology, University of Texas Southwestern, Dallas, Texas, USA.
AD  - Department of Urology, Second Faculty of Medicine, Charles University, Prague, 
      Czech Republic.
AD  - European Association of Urology Research Foundation, Arnhem, Netherlands.
AD  - Institute for Urology and Reproductive Health, Sechenov University, Moscow, 
      Russia.
AD  - Department of Urology, University of Jordan, Amman, Jordan.
FAU - Schmidinger, Manuela
AU  - Schmidinger M
AD  - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 
      Vienna, Austria.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Curr Opin Urol
JT  - Current opinion in urology
JID - 9200621
RN  - C9LVQ0YUXG (Axitinib)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Axitinib
MH  - *Carcinoma, Renal Cell/drug therapy
MH  - Humans
MH  - *Kidney Neoplasms/drug therapy
MH  - Network Meta-Analysis
MH  - Sunitinib
EDAT- 2021/05/10 06:00
MHDA- 2021/06/29 06:00
CRDT- 2021/05/09 20:56
PHST- 2021/05/10 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2021/05/09 20:56 [entrez]
AID - 00042307-202107000-00008 [pii]
AID - 10.1097/MOU.0000000000000889 [doi]
PST - ppublish
SO  - Curr Opin Urol. 2021 Jul 1;31(4):332-339. doi: 10.1097/MOU.0000000000000889.